Tarsus PharmaceuticalsTARS
About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Employees: 323
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
71% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 49
52% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 29
5% more funds holding
Funds holding: 191 [Q1] → 201 (+10) [Q2]
4.95% more ownership
Funds ownership: 104.7% [Q1] → 109.65% (+4.95%) [Q2]
17% less capital invested
Capital invested by funds: $2.24B [Q1] → $1.87B (-$372M) [Q2]
43% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 4 (-3) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Matthew Caufield | 26%upside $72 | Buy Assumed | 27 May 2025 |
Financial journalist opinion
Based on 7 articles about TARS published over the past 30 days
